Healthy Volunteers, Stable Coronary Artery Disease
Conditions
Brief summary
This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).
Interventions
DRUGRO7763505
Participants will receive RO7763505 as per the schedule described in the protocol.
DRUGPlacebo
Participants will receive matching placebo as per the schedule described in the protocol.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Parts 1a, 1b, and 2: Double blind Part 1c: Open-label
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Part 1: * Healthy biologically male and female participants of nonchildbearing potential or childbearing potential with no clinically relevant findings on physical examination at screening or baseline (assessed either on Day -2 or Day -1), including detailed medical and surgical history, vital signs, 12-lead electrocardiogram (ECG), hematology, blood chemistry, serology, and urinalysis * No suspicion of cognitive impairment/dementia as judged by the Investigator Part 2: * Myocardial infarction before the screening visit * Objective imaging evidence (coronary computed tomography \[CT\] angiography or invasive angiography) of coronary atherosclerosis Participants who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) are eligible if the procedure was done \>6 months prior to screening * A diagnosis of stable CAD, defined as being on stable guideline-directed medical therapy (GDMT) if tolerated for at least 90 days prior to screening with no planned changes or scheduled interventions during the study * QTc of \<= 450 milliseconds (ms) as determined by a single 12-lead ECG recording. If the initial ECG result of the triplicate is exclusionary, consecutive repeat ECG results must be within the acceptable limits. In participants with a stable bundle branch block where the QRS duration is \> 120 ms, the QTcF will be calculated as: QTcF - (QRS - 100 ms)
Exclusion criteria
Part 1: * Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator * Vaccination within 28 days prior to Day 1 (non-live vaccines including influenza vaccination are permitted 14 days prior to Day 1) or planned before the end of the study. Investigators are advised to review the immunization status of participants who are considered for treatment with RO7763505 and follow local/national guidance for adult vaccination against infectious disease as they deem relevant * Positive result on human immunodeficiency virus (HIV)-1 and HIV-2, hepatitis B virus (HBV) (either hepatitis B surface antigen \[HBsAg\] or hepatitis B core antibody \[HBcAb\]), hepatitis C virus (HCV) antibody test, or tuberculosis (TB) Part 2: * Individuals with New York Heart Association (NYHA) Class III or IV heart failure * Known or suspected immunocompromised state * Treatment with any investigational therapy within 28 days or within five drug-elimination half-lives (whichever is longer; or longer than either if required by local regulations; if the half-life is unknown, the 90-day period applies) prior to Day 1, calculated from the day of the follow-up from the previous study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 1a and Part 1b: Percentage of Participants With Adverse Events (AEs) | Part 1a: Approximately up to 2 Weeks; Part 1b: Approximately up to 3 Weeks |
| Part 1c: Plasma Concentration of RO7763505 in Fasted and fed State | Approximately up to 3 Weeks |
| Part 2: Percentage of Participants With AEs | Approximately up to 6 Weeks |
Secondary
| Measure | Time frame |
|---|---|
| Part 1a and Part 1b: Plasma Concentration of RO7763505 and its Metabolites | Part 1a: Approximately up to 2 Weeks; Part 1b: Approximately up to 3 Weeks |
| Part 1a and Part 1b: Percentage Change From Baseline in Inhibition of Ex Vivo-Stimulated Interleukin-1 Beta ( IL-1β) | Part 1a: Baseline, Approximately up to 2 Weeks; Part 1b: Baseline, Approximately up to 3 Weeks |
| Part 1c: Percentage of Participants With AEs | Approximately up to 3 Weeks |
| Part 2: Plasma Concentration of RO7763505 and its Metabolites | Approximately up to 6 Weeks |
| Part 2: Percentage Change From Baseline in Inhibition of Ex Vivo-Stimulated IL-1β | Baseline, Approximately up to 6 Weeks |
Countries
Netherlands
Contacts
STUDY_DIRECTORClinical Trials
Hoffmann-La Roche
Outcome results
None listed